Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Open Access
- 1 January 2020
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2), 729-732
- https://doi.org/10.1159/000507850
Abstract
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are established effective therapies in patients with ALK-rearranged advanced non-small-cell lung cancer (NSCLC). Upon progressive disease, patients normally receive a subsequent ALK TKI. However, when disease progression occurs in a limited number of sites, an oligoprogressive approach is a treatment option. In our case, FDG-PET/CT scan detected a progressive site in a patient with ceritinib therapy. Biopsy of the lesion was not possible because of its location. Progression was therefore confirmed by liquid biopsy with identification of the resistant subclone ALK G1202R. Definitive radiotherapy of the progressive site led to the disappearance of the ALK-resistant mutation. Meanwhile, ceritinib therapy was continued. The absence of disease both on repeated imaging and liquid biopsy indicates that eradication of a resistant subclone with an oligoprogressive treatment approach might be possible.Keywords
This publication has 5 references indexed in Scilit:
- Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung CancerClinical Cancer Research, 2018
- Understanding and targeting resistance mechanisms in NSCLCNature Reviews Cancer, 2017
- The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort AnalysisClinical Oncology, 2017
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung CancerCancer Discovery, 2016
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012